COMBINATIONS INCLUDING ABX196 FOR THE TREATMENT OF CANCER

• US 20190328747A1
• Filed: 09/14/2017
• Published: 10/31/2019
• Est. Priority Date: 09/14/2016
• Status: Active Grant

• Current Assignee: Abivax
• Original Assignee: Abivax
• Inventors: CRABE, Sandrine, SCHERRER, Didier, EHRLICH, Hartmut, POULETTY, Philippe
• Granted Patent: US 11,278,552 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/553 having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/7032 attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001104 Epidermal growth factor receptors [EGFR]
• CPC Class Codes: A61K 39/001106 Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
• CPC Class Codes: A61K 39/001124 CD20
• CPC Class Codes: A61K 39/001129 Molecules with a "CD" designation not provided for elsewhere
• CPC Class Codes: A61K 39/001135 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 39/001174 Proteoglycans, e.g. glypican, brevican or CSPG4
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/3955 : against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/39558 : against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: C07K 16/2818 : against CD28 or CD152
• CPC Class Codes: C07K 2317/73 : Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Claims

1. A method of treating cancer, comprising the administration, in a patient in need thereof, of a therapeutically effective amount of an antitumor pharmaceutical combination comprising:

(i) a compound ABX196 of formula (I)

2. The method according to claim 1, wherein the compound ABX196 of formula (I)

3. The method according to claim 1, wherein

the compound ABX196 of formula (I) (i)

4. The method according to claim 1, wherein the compound ABX196 of formula (I) (i)

5. The method according to claim 1, wherein the administrations of the compound ABX196 of formula (I) (i)

11. The method according to claim 1, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cyclophosphamide, epirubicin, idarubicin, mitoxantrone and oxaliplatin.

12. The method according to claim 1, wherein the chemotherapeutic agent is doxorubicin or sorafenib.

13. The method according to claim 1, wherein the immunotherapeutic agent is an antibody specific of a tumor antigen selected from the group consisting of Her2/neu, EGFR, VEGF, CD20, CD52, CD33, TACE, cathepsin S, uPA, uPAR, PD-1, Glypican-3, claudin-3, claudin-4, BMCA and CTLA4.

14. The method according to claim 1, wherein the immunotherapeutic agent is a monoclonal anti-PD1 antibody.

15. The method according to claim 1, wherein the cancer is selected from the group consisting of melanoma, hepatocarcinoma, colorectal cancer and bladder cancer.

6. A method for treating cancer, comprising the administration, in a patient in need thereof, of a therapeutically effective amount of a vaccine composition comprising a compound ABX196 of formula (I)

16. The method according to claim 6, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cyclophosphamide, epirubicin, idarubicin, mitoxantrone and oxaliplatin.

17. The method according to claim 6, wherein the chemotherapeutic agent is doxorubicin or sorafenib.

18. The method according to claim 6, wherein the immunotherapeutic agent is an antibody specific of a tumor antigen selected from the group consisting of Her2/neu, EGFR, VEGF, CD20, CD52, CD33, TACE, cathepsin S, uPA, uPAR, PD-1, Glypican-3, claudin-3, claudin-4, BMCA and CTLA4.

19. The method according to claim 6, wherein the immunotherapeutic agent is a monoclonal anti-PD1 antibody.

20. The method according to claim 6, wherein the cancer is selected from the group consisting of melanoma, hepatocarcinoma, colorectal cancer and bladder cancer.

7. A method for treating cancer, comprising the administration, in a patient in need thereof, of a therapeutically effective amount of a compound ABX196 of formula (I)

8. The method according to claim 7, wherein said combination further comprises an antitumor antigen.

21. The method according to claim 7, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cyclophosphamide, epirubicin, idarubicin, mitoxantrone and oxaliplatin.

22. The method according to claim 7, wherein the chemotherapeutic agent is doxorubicin or sorafenib.

23. The method according to claim 7, wherein the immunotherapeutic agent is an antibody specific of a tumor antigen selected from the group consisting of Her2/neu, EGFR, VEGF, CD20, CD52, CD33, TACE, cathepsin S, uPA, uPAR, PD-1, Glypican-3, claudin-3, claudin-4, BMCA and CTLA4.

24. The method according to claim 7, wherein the immunotherapeutic agent is a monoclonal anti-PD1 antibody.

25. The method according to claim 7, wherein the cancer is selected from the group consisting of melanoma, hepatocarcinoma, colorectal cancer and bladder cancer.

9. A combined preparation comprising:

(i) one or more dosage units of a compound ABX196 of formula (I)

10. The combined preparation for its use according to claim 9, wherein the compound ABX196 of formula (I)